Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement - Summary - MDSpire

Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement

  • By

  • Milda Mikalonytė

  • Vilhelmas Landsbergis

  • Lukas Kevličius

  • Skirmantė Černauskienė

  • Linas Davainis

  • Andrius Žučenka

  • Igoris Trociukas

  • Regina Pileckytė

  • Birutė Davainienė

  • Inga Šlepikienė

  • Gintarė Ražanskienė

  • Ugnius Mickys

  • Jonas Ražanskas

  • Jūratė Dementavičienė

  • Mindaugas Stoškus

  • Raminta Batiuškaitė

  • Laimonas Griškevičius

  • June 9, 2026

  • 0 min

Share

Objective:

To present two cases of ALK-positive anaplastic large cell lymphoma (ALCL) with central nervous system (CNS) involvement, highlighting the challenges and treatment outcomes associated with this condition.

Key Findings:
  • Alectinib, combined with CNS-directed chemotherapy, was effective in both cases of ALK-positive ALCL with CNS involvement, suggesting a potential new treatment pathway.
  • The first patient has remained in remission for over 81 months on alectinib maintenance, indicating long-term efficacy.
  • The second patient has remained in complete remission for 20 months on alectinib maintenance, supporting its use in similar cases.
Interpretation:

These cases suggest that alectinib may be a viable treatment option for ALK-positive ALCL with CNS involvement, warranting further investigation in larger cohorts.

Limitations:
  • The study presents only two cases, limiting the generalizability of the findings and the ability to draw broader conclusions.
  • No standard therapy has been established for ALK-positive ALCL with CNS involvement, highlighting the need for more research.
Conclusion:

Alectinib combined with CNS-directed chemotherapy shows promise in treating ALK-positive ALCL with CNS involvement, but further studies are needed to validate these findings.

Original Source(s)

Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement

  • by Milda Mikalonytė, Vilhelmas Landsbergis, Lukas Kevličius, Skirmantė Černauskienė, Linas Davainis, Andrius Žučenka, Igoris Trociukas, Regina Pileckytė, Birutė Davainienė, Inga Šlepikienė, Gintarė Ražanskienė, Ugnius Mickys, Jonas Ražanskas, Jūratė Dementavičienė, Mindaugas Stoškus, Raminta Batiuškaitė, Laimonas Griškevičius

  • June 9, 2026

Related Content

Neurofilament light and glial fibrillary acidic protein do not reflect neuronal or glial damage during different intracranial radiotherapy regimes: a pilot study

Cross-attention guided multi-modal network for breast ultrasound diagnosis incorporating objective clinical semantics

Case Report: early regression and bladder-intact survival after limited-course immunotherapy-based systemic therapy in two patients with clinically staged bulky muscle-invasive bladder cancer